Allarity Therapeutics Inc (ALLR) Stock Analysis
Verdict: AVOID
Severe cash burn with ~12 months runway and chronic dilution risk eclipse early Phase 2 pipeline potential.
Investment score: 25/100
Analysis as of
Is Allarity Therapeutics Inc stock worth reviewing? AI model thesis
The AI model rates ALLR as AVOID due to an acute cash runway constraint (~12 months), severe dilution history, and clinical execution risks in early-stage oncology.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 25/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Allarity Therapeutics Inc opportunities and risks
What speaks for ALLR
- Stenoparib Phase 2 clinical advancement in ovarian cancer
What speaks against ALLR
- Imminent cash exhaustion and severe shareholder dilution
Frequently asked questions about Allarity Therapeutics Inc (ALLR)
Is ALLR stock a good investment?
The cached TradeMates AI model rates Allarity Therapeutics Inc as AVOID with an investment score of 25/100. The AI model rates ALLR as AVOID due to an acute cash runway constraint (~12 months), severe dilution history, and clinical execution risks in early-stage oncology. This is algorithmic model output, not personal investment advice.
Is ALLR stock a buy?
The TradeMates model verdict for ALLR is AVOID with an investment score of 25/100. Treat this as a model signal to review, not a personal buy recommendation.